posted
LOS ANGELES, Jul 6, 2005 (PRIMEZONE via COMTEX) -- Cord Blood America, Inc. (CBAI, Trade), an umbilical cord blood stem cell preservation company, is pleased to announce the launch of its Partners' Circle sales and marketing program. The purpose of The Partners' Circle is to rapidly build a nationwide network of motivated individuals to provide marketing information on behalf of Cord Blood America's subsidiary -- Cord Partners -- in order to capitalize on the rapidly expanding market for cord blood stem cell preservation.
The Partners' Circle will comprise a special group of people who believe in the life-saving potential of umbilical cord blood stem cells. They share Cord Partners' information with expectant parents, and earn additional income when these parents become Cord Partners' customers. The Partners' Circle is open to qualified individuals that are excited about the opportunity of promoting the lifesaving benefits of umbilical cord blood preservation to expectant parents.
"We are happy to offer this program to a special group of people who feel that cord blood preservation is an important medical issue," stated Matthew Schissler, President of Cord Blood America. "With the initial guidance of the Cord Blood America staff, we believe these special individuals will be able to grow our business model through the power of word of mouth marketing that will drive referral sales and help many expectant parents along the way. We've learned this lesson from mature industries that prove viral marketing and product placement works. As such, we will set the bar for the cord blood industry using individuals who care about the future health benefits of stem cells." added Mr. Schissler.
In launching The Partners' Circle, the Company recognized the power of the personal referral due to its significant corporate advantages that include the following:
-- Rapid deployment across the entire U.S. market without logistical delays; -- No capital expenditures related to leaseholds and equipment; -- Significantly reduced monthly operating expenses related to rent, supplies and administration. -- Controllable compensation expenses due to pay-for-performance network model vs. fixed monthly salaries in sales force model. -- Centralized control and decision making vs. satellite offices with expensive management requirements. For more information please go to the Partners' Circle website at: http://www.partnerscircle.com.
This press release is available on the Cord Blood America IR HUB for investor commentary, feedback and questions. Investors are asked to visit http://www.agoracom.com/IR/CordBloodAmerica . Alternatively, investors are asked to e-mail all questions and correspondence to CBAI@agoracom.com where they can also request addition to the investor e-mail list to receive all future press releases and correspondence directly.
About Cord Blood America
Cord Blood America (CBAI, Trade) is the parent company of Cord Partners, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and life-saving resource for treating a growing number of ailments, including cancer, leukemia, or blood and immune disorders. For more information on how this precious lifeline can benefit your family, visit www.cordpartners.com.
Forward-Looking Statements
This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. Forward-looking statements include, without limitation, our ability to increase income streams, to grow revenue and earnings, and to obtain additional cord blood banking revenue streams. These statements are only predictions and are subject to certain risks, uncertainties and assumptions, which are identified and described in the Company's public filings with the Securities and Exchange Commission.
posted
LOS ANGELES, Jul 13, 2005 (PRIMEZONE via COMTEX) -- Cord Blood America, Inc. (CBAI, Trade), an umbilical cord blood stem cell preservation company, is pleased to announce the appointment of Gayl Rogers Chrysler to the Board of Directors.
Ms. Chrysler has more than 25 years of experience in the blood banking and the cord blood banking industries. Since 2003, she has been the National Director of Operations, Cord Blood Program for the National American Red Cross. In this role she leads the development and implementation of strategy systems and partnerships to achieve optimal efficiency and the highest product quality at national collection and storage sites.
-- As the Cord Blood Bank Manager for the American Red Cross, North Central Blood Services from 1998-2003, Ms. Chrysler provided overall management to the Cord Blood Bank in its seven days a week, 24-hour a day operation to procure cord blood from delivering mothers at numerous hospitals. In addition, she ensured the development and implementation of local operating policies and procedures, served as the external liaison to hospitals and donors, and managed the financial outcome of the program. -- As a consultant to the National American Red Cross from 1993-1995, Ms. Chrysler represented the American Red Cross Tissue Services National Headquarters at national meetings of North American Transplant Coordinators Organizations. Additionally, she provided consultation services to the American Red Cross Tissue Services National Headquarters on preliminary development of national standardized training. -- As Director of Transplant Donor Services for the American Red Cross between 1986-1993, Ms. Chrysler provided direction for the management of program implementation, project/research coordination, and policy development of the regional organ and tissue procurement organization (OPO) for Minnesota, North Dakota, and South Dakota.. Ms. Chrysler holds a M.B.A. in Health Care from the University of Saint Thomas, St. Paul, Minnesota and a B.A.N. from the College of Saint Catherine. Ms. Chrysler is also a Certified/Registered Nurse.
Matthew Schissler, Chairman and CEO of Cord Blood America stated, "A powerful component to our growth strategy is the implementation of a superior Board of Directors that will help guide Cord Blood America during this phase of rapid growth and development. Ms. Chrysler is just such a person and will provide invaluable insight and experience as we move toward becoming the leader in cord blood stem cell preservation."
"I view cord blood collection and storage as a critical and essential element of health care in America," stated Ms. Chrysler. "Cord Blood America has demonstrated an ability to combine business execution with genuine empathy for the well being of Americans, so I accept my appointment to the board with great pride and enthusiasm."
This press release is available on the Cord Blood America IR HUB for investor commentary, feedback and questions. Investors are asked to visit http://www.agoracom.com/IR/CordBloodAmerica . Alternatively, investors are asked to e-mail all questions and correspondence to CBAI@agoracom.com, where they can also request addition to the investor e-mail list to receive all future press releases and correspondence directly.
About Cord Blood America
Cord Blood America is the parent company of Cord Partners, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and life-saving resource for treating a growing number of ailments, including cancer, leukemia, or blood and immune disorders. For more information on how this precious lifeline can benefit your family, visit www.cordpartners.com.
Forward-Looking Statements
This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. Forward-looking statements include, without limitation, our ability to increase income streams, to grow revenue and earnings, and to obtain additional cord blood banking revenue streams. These statements are only predictions and are subject to certain risks, uncertainties and assumptions, which are identified and described in the Company's public filings with the Securities and Exchange Commission.
posted
LOS ANGELES, Jul 19, 2005 (PRIMEZONE via COMTEX) -- Cord Blood America, Inc. (CBAI, Trade), an umbilical cord blood stem cell preservation company, is pleased to provide this second installment in a series of Corporate Updates. The purpose of this information campaign is to provide both Cord Blood America investors and the investment community as a whole with a comprehensive overview of the Company, its services and its industry during a time of rapid growth and development.
In this corporate update, our focus is on the outlook for the umbilical cord blood Industry.
GENERAL
The industry has seen significant growth over the past year, as education and awareness about the benefits of preserving umbilical cord blood proliferates among expectant parents and the general populous. A significant catalyst took place on May 24, 2005 when the House of Representatives, by a virtually unanimous vote, passed Bill HR-2520. The bill promises to boost research using adult stem cells, bone marrow, and cells from umbilical cord blood. The bill also served to differentiate the benefits of using stem cells from acceptable umbilical cord blood, as opposed to the controversial use of embryonic stem cells. Cord Blood America only preserves stem cells from umbilical cord blood. Through potential creation of alliances, Cord Blood America may position itself to be a beneficiary of Bill HR 2520. In addition, the Company may indirectly be the beneficiary of any new developments from the research firms involved with the bill.
The cord blood industry is estimated to be valued at $250M in 2005. According to the latest census numbers, there were 4.18 Million births in the United States this past year. The mission of Cord Blood America is to significantly raise education and awareness levels among expectant parents, leading to the selection of Cord Blood America over other competitors. The Company's recently released first quarter financials clearly indicate Cord Blood America is succeeding in accomplishing this goal. First Quarter 2004 revenues increased 201% compared to First Quarter 2003.
The industry is already receiving significant news coverage and awareness on all levels:
Political - Through the passing of Bill HR-2520 Consumer - Over 70 diseases can now be treated by stem cells Business - The industry continues to grow quarter over quarter, while Cord Blood America has posted nine straight quarters of growth that surpass industry levels. This unequivocally demonstrates Cord Blood America is growing in terms of both revenues and market share. KEYS TO SUCCESS
Cord Blood America has many advantages over current competitors and companies that want to enter this industry. Its main keys to success are as follows:
-- Licensed by PharmaStem Inc. - Patent Holder to Stem Cell Preservation -- Partnered with an AABB (American Association of Blood Banks) Certified Lab, that serves as the single exclusive processing and storage facility for the Company. -- The samples from their partner laboratory have resulted in 34 Successful Transplants -- The lab has been in existence for over 50 years and have been specializing in Cord Blood Storage since 1996 -- Provides a Fixed Cost of Good Sold (COGS) -- Partnered with the industry's premier medical courier providing the company with 24 x7 service throughout the U.S. and a fixed COGS -- Fully dedicated sales and customer service team -- Ability to monetize parent database with other products and services creating a complete marketing effort -- Management team has been together for 10 years, creating shareholder value for various companies -- Well financed for short and long term growth -- Less than 1% of customers have defaulted on payment of contracts, showing the long term viability of the annual contracts -- Recent appointment of Gayl Rogers Chrysler, National Director of Operations, Cord Blood Program for the National American Red Cross to our board of directors serves as significant third-party validation that Cord Blood America will be a leader in this space NEW REVENUE STREAMS AND ACQUISITION STRATEGY
The barriers to entry in this industry are now significantly high and include, amongst other things, large start up costs, the need for a PharmaStem license to use core technology and the markets unwillingness to accept new entrants.
Theses barriers will help Cord Blood America expand its business through internal growth, acquisitions and new revenue streams.
New Revenue Streams - Although the company continues to focus on the end user, Cord Blood America launched its B2B model, Cord Blood America Professional Services, in November of 2004.
Acquisitions - The plan is to aggressively consolidate the market. Specifically, there are presently a number of small "boutique" operations in this space that appear to be feeling the pressure of the above mentioned barriers, thereby, presenting Cord Blood America with an opportunity to absorb these operations, eliminating duplication and creating am efficient and formidable market leaders. The Company expects any such roll up will result in the existence of 5-6 major players, with Cord Blood America taking one of the leadership positions.
Internal Growth - In addition to the internal sales team, the Company has, and will continue to aggressively add a field sales force and contract employees to build relationships with other channels, including physicians, hospitals and clinics. The company has also announced their Partner's Circle Program (Press Release dated July 6, 2005) to increase referrals.
This press release is available on the Cord Blood America IR HUB for investor commentary, feedback and questions. Investors are asked to visit http://www.agoracom.com/IR/CordBloodAmerica . Alternatively, investors are asked to e-mail all questions and correspondence to CBAI@agoracom.com where they can also request addition to the investor e-mail list to receive all future press releases and correspondence directly.
About Cord Blood America
Cord Blood America (CBAI, Trade) is the parent company of Cord Partners, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and life-saving resource for treating a growing number of ailments, including cancer, leukemia, or blood and immune disorders. For more information on how this precious lifeline can benefit your family, visit www.cordpartners.com.
Forward-Looking Statements
This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. Forward-looking statements include, without limitation, our ability to increase income streams, to grow revenue and earnings, and to obtain additional cord blood banking revenue streams. These statements are only predictions and are subject to certain risks, uncertainties and assumptions, which are identified and described in the Company's public filings with the Securities and Exchange Commission.
posted
I have been watching this stock. I think that it could be good for a long term hold or even a quick double your money. It has been holding at .0003 and fighting to break free every day. It is just a matter of time until it gets the recognition. Let me know what you guys think.
Posts: 88 | From: Indiana | Registered: Jun 2005
| IP: Logged |
posted
Disregard I ment that is was sitting at .0048 for the last two days. I copied the wrong symbol into the title it should be CBAI. My bad.
Posts: 88 | From: Indiana | Registered: Jun 2005
| IP: Logged |
posted
ok once again sorry, youare right it is .48. I think all the numbers flashing in my face are getting to me. I think I will go back to bed.
Posts: 88 | From: Indiana | Registered: Jun 2005
| IP: Logged |
posted
Lawguns stop drinking dude. Either that or you so happy you got in at .0048 Sell now... my god someone's fat finger couldve made you rich.
Posts: 2362 | From: BEENEVERYWHERE | Registered: Mar 2005
| IP: Logged |
posted
Sounds good to me YaYa. Let this thread die in peace while I get another shot and a beer. I will try to get it right next time.
Posts: 88 | From: Indiana | Registered: Jun 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
